Case Reports in Oncology最新文献

Retraction Statement: Paper by Rudrakshi Mahaldar, Saurabh Raj, Anindya Halder, Vijay Kannaujiya, Dhiraj Mallik, Banyeswar Pal, Bishal Saha, Subhra Banerjee, Shafayat Anjum, Subinay Mandal, Vinesh B and Shreya Chopra entitled "Rare Presentation of Spontaneous Transomental Hernia in an Elderly Oncology Patient: Diagnostic Vigilance and Surgical Management" [Case Rep Oncol. 2025;18:1307-1313; https://doi.org/10.1159/000548259]. 撤回声明：Rudrakshi Mahaldar， Saurabh Raj, Anindya Halder, Vijay Kannaujiya, Dhiraj Mallik, Banyeswar Pal, Bishal Saha, Subhra Banerjee, Shafayat Anjum, Subinay Mandal， Vinesh B和Shreya Chopra题为“老年肿瘤患者自发性突发性疝的罕见表现：诊断警觉和手术管理”的论文[病例报告杂志，2025;18:13 37 -1313；https://doi.org/10.1159/000548259]。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-31 eCollection Date: 2026-01-01 DOI: 10.1159/000553062

引用次数: 0

Case Report: Rapid Improvement of Chronic Lymphocytic Leukemia Infiltration of the Scalp by BCL2-Inhibitor. 病例报告：bcl2抑制剂快速改善头皮慢性淋巴细胞白血病浸润。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-22 eCollection Date: 2026-01-01 DOI: 10.1159/000551956

Sike Esther Mbonde Mouangue, Dimitrios Deligkas, Dimitrios Vogdos, Maria Mainou, Euthimia Vlachaki

引用次数: 0

Giant Breast Angiosarcoma in a 20-Year-Old Young Adult Female: A Case Report and Review of Literature. 20岁年轻成年女性巨大乳腺血管肉瘤1例报告及文献复习。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-21 eCollection Date: 2026-01-01 DOI: 10.1159/000553620

Jingkun Wang, Zhiquan Chen, Yufeng Wang, Xinhai Wang, Jingbo Yang, Haojun Xuan

{"title":"Giant Breast Angiosarcoma in a 20-Year-Old Young Adult Female: A Case Report and Review of Literature.","authors":"Jingkun Wang, Zhiquan Chen, Yufeng Wang, Xinhai Wang, Jingbo Yang, Haojun Xuan","doi":"10.1159/000553620","DOIUrl":"10.1159/000553620","url":null,"abstract":"Introduction: Primary breast angiosarcoma (PAS) is an extremely rare vascular malignancy that typically presents as a breast mass or cutaneous changes. Given its highly aggressive nature, rapid progression, and early metastasis that result in a poor prognosis, coupled with a lack of standardized treatment guidelines, there is an urgent need to develop novel, effective therapeutic strategies.Case presentation: This report focused on a 20-year-old Uyghur woman presenting with a painless, rapidly enlarging mass in the left breast. Staging evaluation with breast MRI, whole-body contrast-enhanced CT, and bone scintigraphy revealed a large (10 × 7 cm) primary tumor and bilateral axillary lymphadenopathy suspicious for metastasis, with no evidence of distant disease (cT3N1M0, stage III). The high-grade angiosarcoma was confirmed through a core needle biopsy of the breast mass. With no remarkable medical or family history of breast cancer, the patient underwent complete surgical resection of the breast angiosarcoma, which provided a definitive pathological diagnosis. Given negative lymph node biopsy results, axillary lymph node dissection was not performed. Postoperatively, the patient received adjuvant chemotherapy with paclitaxel and bevacizumab. The regimen was well tolerated, and no disease recurrence was observed during follow-up. This case exemplified a practical management strategy for PAS, emphasizing the key role of clinical presentation and conventional imaging in guiding surgical decisions, particularly in resource-limited settings.Conclusions: As a rare, highly malignant tumor, PAS requires early diagnosis and multidisciplinary management, including thorough metastasis evaluation and personalized therapy, to optimize survival and quality of life.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1289-1299"},"PeriodicalIF":0.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Reports of Four Patients with HPV-Positive Head and Neck Cancer of Non-Oropharyngeal Origin Undergoing Liquid Biopsy for Circulating Cell-Free HPV-DNA before, during, and after Treatment. 4例非口咽源性hpv阳性头颈癌患者在治疗前、治疗中及治疗后行循环游离HPV-DNA液体活检的病例报告

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-21 eCollection Date: 2026-01-01 DOI: 10.1159/000553662

Mark Zupancic, Madeleine Birgersson, Tina Dalianis

{"title":"Case Reports of Four Patients with HPV-Positive Head and Neck Cancer of Non-Oropharyngeal Origin Undergoing Liquid Biopsy for Circulating Cell-Free HPV-DNA before, during, and after Treatment.","authors":"Mark Zupancic, Madeleine Birgersson, Tina Dalianis","doi":"10.1159/000553662","DOIUrl":"https://doi.org/10.1159/000553662","url":null,"abstract":"Introduction: Human papillomavirus (HPV) is a risk factor for oropharyngeal squamous cell carcinoma (OPSCC) and is sometimes found in other head and neck squamous cell carcinomas (HNSCCs), where its role is not as clearly defined. To gain more knowledge regarding response to therapy, and the monitoring of cell-free HPV DNA (cfHPV-DNA) in plasma in HPV-positive (HPV+) non-OPSCC HNSCC, the presence and levels of cfHPV-DNA in the plasma of four patients were followed before, during, and after therapy and correlated to treatment response.Case presentations: Two HPV+ nasopharyngeal cancer patients, one HPV+ lacrimal gland carcinoma patient, and one HPV+ hypopharyngeal carcinoma patient were examined for the presence of cfHPV-DNA in plasma using droplet digital PCR assaying for HPV16 or 35. At diagnosis, the HPV35+ nasopharyngeal carcinoma patient and the HPV16+ hypopharyngeal carcinoma patient were positive for cfHPV-DNA, which subsequently cleared rapidly after a favorable treatment response. The second patient with a nasopharyngeal carcinoma (HPV16+, T1N0M0) was cfHPV-DNA negative at all time points. The patient with an HPV16+ lacrimal duct carcinoma lacked a plasma sample at diagnosis, and the sample taken immediately after surgical removal of the patient's tumor was cfHPV-DNA negative. However, this patient turned cfHPV-DNA positive in plasma 3-4 weeks after initiation of radiotherapy, with increasing cfHPV-DNA values during further follow-up, but after treatment for a then detected locoregional relapse became cfHPV-DNA negative again.Conclusion: Monitoring cfHPV-DNA in plasma could be useful for following treatment response also in HPV+ non-OPSCC HNSCC; however, larger cohorts are needed to confirm these findings.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1275-1282"},"PeriodicalIF":0.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spontaneous Bilateral Perirenal Hemorrhage during Chemotherapy with Liposomal Paclitaxel and Cyclophosphamide in Breast Cancer: A Case Report. 乳腺癌紫杉醇和环磷酰胺脂质体化疗期间自发性双侧肾周出血1例。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-21 eCollection Date: 2026-01-01 DOI: 10.1159/000553618

Lin Lv, Xiaohui Wang, Xiaotao Zhu

{"title":"Spontaneous Bilateral Perirenal Hemorrhage during Chemotherapy with Liposomal Paclitaxel and Cyclophosphamide in Breast Cancer: A Case Report.","authors":"Lin Lv, Xiaohui Wang, Xiaotao Zhu","doi":"10.1159/000553618","DOIUrl":"https://doi.org/10.1159/000553618","url":null,"abstract":"Introduction: Spontaneous perirenal hemorrhage (SPH) is rare and has not been previously linked to the combination of liposomal paclitaxel and cyclophosphamide. To our knowledge, this is the first reported case of bilateral SPH temporally associated with this chemotherapy regimen.Case presentation: A 49-year-old woman with stage IA breast cancer developed sequential bilateral perirenal hematomas after receiving liposomal paclitaxel plus cyclophosphamide, with inferred onset around day 19 of cycle 3 on the left and around day 16 of cycle 4 on the right. Imaging and laboratory analyses showed no evidence of renal neoplasm, obvious vascular abnormalities, nephrolithiasis, or hematologic or coagulation disorders. Preexisting Bosniak I renal cysts were present but showed no radiological evidence of rupture. Both events appeared to have occurred in the third week after infusion, suggesting a possible temporal pattern. The underlying mechanism remains speculative, and competing etiologies, including polyarteritis nodosa, could not be definitively excluded. The patient was managed conservatively, and both hematomas resolved within 90 days.Conclusion: This case suggests a possible temporal association between chemotherapy using liposomal paclitaxel plus cyclophosphamide and SPH, although it is not possible to determine causality from a single report. The development of new abdominal or flank pain during treatment, particularly in the third week after infusion, should prompt consideration of renal imaging. Serial ultrasonography may be useful for follow-up during conservative management.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1246-1253"},"PeriodicalIF":0.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deep-Seated Kaposiform Hemangioendothelioma Presenting with Recurrent Hemorrhagic Episodes: A Diagnostic Challenge. 以复发性出血发作为表现的深部卡西样血管内皮瘤：一个诊断挑战。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-21 eCollection Date: 2026-01-01 DOI: 10.1159/000553370

Mária Füssiová, Dominika Dóczyová, Peter Švec, Ján Blatný, Denise M Adams, Peter Rohoň, Monika Grešíková, Zlatica Pavlovičová, Svorad Trnovec, Vlasta Haramiová, Júlia Horáková, Ivana Boďová, Jaroslava Adamčáková, Tomáš Sýkora, Miroslava Pozdechová, Alexandra Kolenová

{"title":"Deep-Seated Kaposiform Hemangioendothelioma Presenting with Recurrent Hemorrhagic Episodes: A Diagnostic Challenge.","authors":"Mária Füssiová, Dominika Dóczyová, Peter Švec, Ján Blatný, Denise M Adams, Peter Rohoň, Monika Grešíková, Zlatica Pavlovičová, Svorad Trnovec, Vlasta Haramiová, Júlia Horáková, Ivana Boďová, Jaroslava Adamčáková, Tomáš Sýkora, Miroslava Pozdechová, Alexandra Kolenová","doi":"10.1159/000553370","DOIUrl":"https://doi.org/10.1159/000553370","url":null,"abstract":"Introduction: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor frequently complicated by Kasabach-Merritt phenomenon (KMP).Case presentation: A 21-month-old boy presented with an initial spontaneous scalp hematoma, recurrent hemorrhagic episodes, and progressive consumptive coagulopathy. Imaging revealed an extensive peri- and paravertebral infiltrative mass involving the thoracic and lumbosacral spine, consistent with KHE. Biopsy was deferred because of high bleeding risk. Treatment with sirolimus led to rapid clinical and hematologic remission. At 3.5 years of follow-up, the patient remains free of recurrent KMP with sustained disease control and mild radiological regression.Conclusion: This case highlights the diagnostic challenges of deep-seated KHE and the pivotal role of imaging when biopsy is unsafe.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1261-1267"},"PeriodicalIF":0.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent Adenocarcinoma and Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach: A Case Report and Narrative Literature Review. 并发胃腺癌及粘膜相关淋巴组织淋巴瘤1例报告及文献回顾。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-18 eCollection Date: 2026-01-01 DOI: 10.1159/000553248

Sarah A Elkourashy, Ahmad Hamdan, Yousef Al-Asa'd, Mahir Petkar

{"title":"Concurrent Adenocarcinoma and Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach: A Case Report and Narrative Literature Review.","authors":"Sarah A Elkourashy, Ahmad Hamdan, Yousef Al-Asa'd, Mahir Petkar","doi":"10.1159/000553248","DOIUrl":"10.1159/000553248","url":null,"abstract":"Introduction: The synchronous presentation of two distinct primary malignancies in the stomach, specifically gastric adenocarcinoma (GAC) and mucosa-associated lymphoid tissue (MALT) lymphoma, is an extremely rare clinical entity. These dual primary tumors challenge standard management protocols due to their differing biologies.Case presentation: We present a case of a patient diagnosed with concurrent GAC and MALT lymphoma who was also found to have a pulmonary nodule, creating a complex staging dilemma. Surgical pathology revealed distinct neoplastic entities: gastroesophageal junction adenocarcinoma, gastric MALT lymphoma, and a pulmonary hamartoma. We provide a narrative review of selected cases from the literature to contextualize this finding.Conclusion: Our observations suggest that in such complex presentations, the prognosis is often driven by the higher-grade malignancy, necessitating a multidisciplinary approach to distinguish between metastatic disease and synchronous benign or indolent lesions.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1300-1311"},"PeriodicalIF":0.7,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13529300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weekly Metronomic Venetoclax and Decitabine/Cedazuridine in Acute Myeloid Leukemia Patient Declining Blood Transfusion. 急性髓系白血病患者输血减少的每周节律性维妥乐和地西他滨/Cedazuridine

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-15 eCollection Date: 2026-01-01 DOI: 10.1159/000551645

Mahmood Aldapt, Talha Badar, Antoine N Saliba, James Foran, Sidney Bianco, Catherine Hanratty, Hemant Murthy

{"title":"Weekly Metronomic Venetoclax and Decitabine/Cedazuridine in Acute Myeloid Leukemia Patient Declining Blood Transfusion.","authors":"Mahmood Aldapt, Talha Badar, Antoine N Saliba, James Foran, Sidney Bianco, Catherine Hanratty, Hemant Murthy","doi":"10.1159/000551645","DOIUrl":"https://doi.org/10.1159/000551645","url":null,"abstract":"Introduction: Acute myeloid leukemia (AML) treatment typically involves intensive chemotherapy associated with prolonged cytopenias and frequent transfusion requirements. Patients who decline blood products, such as Jehovah's Witnesses (JW), present a therapeutic challenge, as transfusion support is integral to standard care. Emerging low-intensity regimens combining venetoclax (VEN) with hypomethylating agents offer a potential alternative with reduced myelosuppression.Case presentation: A 77-year-old male JW with AML with myelodysplastic syndrome-related changes and mutations in DDX41, ASXL1, and PPM1D presented with pancytopenia. Due to refusal of transfusions, he was treated with a metronomic, all-oral regimen of VEN 400 mg weekly and decitabine/cedazuridine (DEC-C) 35/100 mg weekly, supported by erythropoiesis-stimulating agent (darbepoetin alfa) and thrombopoietin agonist (romiplostim) as needed. After 4 weeks, bone marrow blasts decreased from 20-25% to 10%, with clearance of ASXL1 and PPM1D mutations and reduction of DDX41 variant allele frequency (VAF) to 2.9% from 9.7%. At 26 weeks, marrow blasts further decreased to 5%, DDX41 VAF remained low (2.6%), and counts normalized (ANC 1.73 × 103/µL, hemoglobin 13.1 g/dL, PLT 256 × 103/µL) without any transfusions.Conclusion: This case demonstrates that a metronomic, all-oral VEN and DEC-C regimen can achieve hematologic improvement and molecular response in AML while maintaining transfusion independence. It highlights a feasible and safe therapeutic option for patients declining blood products, achieving disease control with minimal toxicity.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1268-1274"},"PeriodicalIF":0.7,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13493111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unusual Presentation of Triple-Negative Breast Cancer in a Young Woman with Xeroderma Pigmentosum: A Case Report. 年轻女性色素性干皮病罕见的三阴性乳腺癌表现：1例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-14 eCollection Date: 2026-01-01 DOI: 10.1159/000552862

Bashaer Alsaati, Reem Ujaimi, Noura Trabulsi, Atlal Abusanad

{"title":"Unusual Presentation of Triple-Negative Breast Cancer in a Young Woman with Xeroderma Pigmentosum: A Case Report.","authors":"Bashaer Alsaati, Reem Ujaimi, Noura Trabulsi, Atlal Abusanad","doi":"10.1159/000552862","DOIUrl":"10.1159/000552862","url":null,"abstract":"Introduction: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA repair disorder, resulting from defects in nucleotide excision repair, that predisposes affected individuals to multiple cancers, particularly skin malignancies. Internal tumors including breast cancer are uncommon. Triple-negative breast cancer (TNBC) is an aggressive subtype that presents unique therapeutic challenges, particularly in XP patients where radiotherapy is contraindicated.Case presentation: We report a 34-year-old woman with XP who presented with a 6-cm right breast mass. Histopathology revealed grade III invasive carcinoma of no special type (NST) ER-negative, PR low positivity (1-2% of cells), HER2-negative (score 0), Ki-67 >80%. BRCA1/2 testing was negative. She underwent four cycles of neoadjuvant doxorubicin/cyclophosphamide with limited response, followed by modified radical mastectomy with axillary lymph node dissection. Pathology confirmed residual 60 mm tumor with negative surgical margins and fifteen negative lymph nodes. Pathological stage: pT3pN0M0 (AJCC 8th edition). She subsequently received adjuvant paclitaxel plus carboplatin. Radiotherapy was omitted due to XP-related radiosensitivity. At 12 months, the patient remained disease-free.Conclusion: TNBC in XP is exceedingly rare and presents complex management challenges. Platinum-based chemotherapy is biologically rational given the underlying NER defect and may be particularly effective given underlying DNA repair defects, while radiotherapy avoidance necessitates surgical prioritization and PARP inhibitors may represent promising future strategies.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1283-1288"},"PeriodicalIF":0.7,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abemaciclib-Associated Psychosis: A Case Report of a Rare Neuropsychiatric Adverse Effect during Breast Cancer Treatment. abemaciclib相关精神病：乳腺癌治疗期间罕见的神经精神不良反应1例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2026-07-14 eCollection Date: 2026-01-01 DOI: 10.1159/000553560

Alexander Chih-Chieh Chang, Elizabeth Hale, Julia Foldi

{"title":"Abemaciclib-Associated Psychosis: A Case Report of a Rare Neuropsychiatric Adverse Effect during Breast Cancer Treatment.","authors":"Alexander Chih-Chieh Chang, Elizabeth Hale, Julia Foldi","doi":"10.1159/000553560","DOIUrl":"https://doi.org/10.1159/000553560","url":null,"abstract":"Introduction: Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor widely used in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative advanced and early breast cancer. While generally well-tolerated, neuropsychiatric adverse effects are uncommon but may be clinically significant.Case presentation: We report the case of a 72-year-old Caucasian female with stage I endometrial cancer and invasive ductal carcinoma of the breast who developed severe psychotic symptoms approximately 2 weeks after initiating abemaciclib, as part of her adjuvant breast cancer treatment. Her prior treatment had included adjuvant carboplatin and paclitaxel chemotherapy with brachytherapy, and her endocrine therapy was switched from anastrozole to letrozole at the time abemaciclib was added. Despite having a history of anxiety and obsessive-compulsive tendencies, she had no prior psychotic episodes. Her symptoms ultimately required two emergency department visits and a 9-day psychiatric hospitalization. Treatment with mirtazapine, olanzapine, and clonazepam resulted in the complete resolution of psychotic symptoms, and abemaciclib was permanently discontinued. After approximately 9 months, she was able to discontinue psychiatric medications without relapse of her psychotic symptoms.Conclusion: This case highlights the importance of recognizing rare but serious neuropsychiatric adverse effects of abemaciclib and emphasizes the need for careful monitoring and multidisciplinary management.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1231-1238"},"PeriodicalIF":0.7,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13480978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0